The Playground

    W's account. Not fully explained but if he is lumping together all patients > 70 he is deliberately getting Simpson's Paradox.


    Here is somone doing the analysis with proper expalnatuion - so if you don't believe it you can say exactly where it is wrong. It would be very helpful for W to either do that, or accept the analysis. It deals with all-cause deaths which is the most artifact-free measure, and shows clearly why large age ranges cause misleading results:


    What do UK data say about real world impact of vaccines on all cause deaths?
    To what extent is societal vaccination saving lives? Are the vaccines really safe? Some active vaccine skeptics will present bits of data suggesting the…
    www.covid-datascience.com


    And, for fun, how about this?


    Is watching the 1984 Ghostbusters movie killing people? A Statistician's Perspective
    Is watching the 1984 Ghostbusters movie killing people? English adults under 60 who have watched the 1984 Ghostbusters movie are dying at twice the rate of…
    www.covid-datascience.com


    W would, by analogous arguments to what he uses for vaccine efficacy, undoubtedly think that watching 1984 ghostbusters killed people.

    Quote from stefan

    The recent numbers seam to say that, yes it helps to vaccinate, but not nearly as much as the narrative

    If you are younger than 50 you need non vaccine at all. As said we have one CoV-19 death about every 6 week in this group.


    You use the right wording: I believe "vaccines" do protect. This, just believing is the correct wording. No proper study has been done so far. Figures for efficiency given by Pfizer/Moderna/J&J/OxfordAstra are just fake news. Same as the conclusion we win 1:0 after 5 minutes of the game.


    What we had to learn: Gene therapies (aka "vaccines" )work better in younger than older patients - same with cancer chemo. Duration of protection for older is much shorter due to the antibody selected (ACE-2 lock). Chronic inflammations will consume them - a problem that is age dependent.


    Lets hope NOVAVAX will not have this problem despite it also uses a bound S1 protein embedded in a matrix. So just immune cells can check it. With RNA therapy the monoclonal antibodies are produced as long as cells shed the S1. The immune system will not do it for you after a re-infection.

    Moderna uses 2 different proteins. This points into the direction where research must go. So if S1 fails there is the other one still working.

    Regeneron an others identified about 20 antibodies and even better ones have recently be found by Swiss group. So a real vaccine should use at least 3-5 what makes virus mutations a no brainer.

    Quote from THHuxleynew

    proper expalnatuion

    Great wording. Matches the stuff you link.


    May be you did not read my post. It contains cut & paste original data. I did not cluster age groups only you try to sell us such faked data that includes babies too...


    Bad for your FM/R/B friends. UK ICU's are full of double vaxx people just by writing the contrary these will not disappear. I start to believe you suffer from vaccine damage. Did you booster?, then look what will happen in Israel soon....

    Oh they changed the title of the graphs, it now longer says covid death rates. Good. But so many confounders then that those numbers are not possible to judge much without a much much more detailed analysis. W:s tables are a bit better to validate and among those that are old it goes between 2x and 4x worse without 2 jabs. Also Your table is non adjusted figures and you should correct against risk factors and also social group (e.g. exercise is correlated with social groupings).

    Quote from Nar

    The UK stats given are clearly not ICU stats though. I don't know what the ICU stats are.

    Wyttenbach knows of course. Maybe he can find out the sources of the numbers of those who need intensive care and ventilation (probably a fraction of those in the table who show up at emergency care and require more care and overnight stay...)?

    Israeli Experts Warn Vaccine Immunity is on the Wane as Cases Nearly Double & R Number Rises


    Israeli Experts Warn Vaccine Immunity is on the Wane as Cases Nearly Double & R Number Rises
    In an article in the Israeli daily HaAretz, the health panel advising Israel’s government “believes another covid wave is on the horizon in light of
    trialsitenews.com


    In an article in the Israeli daily HaAretz, the health panel advising Israel’s government “believes another covid wave is on the horizon in light of waning vaccine effectiveness.” The article goes on to claim that even though a vaccine drive for children between five and eleven is beginning, this will not slow a new onslaught of COVID-19. TrialSite is monitoring multiple health centers in Israel to determine the effectiveness of this last mass booster program. New cases shot up—nearly doubled on Monday, November 22. If this trend continues, serious questions about mass vaccination must be immediately raised.


    Israel experienced high levels of breakthrough infections which led to the nationwide booster program by late summer. By October reports of success were ubiquitous in mainstream media. By mid-October the New York Times reported fully vaccinated in Israel would include three jabs. German media DW highlighted just a couple of weeks ago that the booster program paid off. Kids were the last frontier.


    In the meantime, in the Palestinian Territories cases continued to be low with low full vaccination rate of about 28%. Why have the case infection rate been so much lower in these areas since the spring? It could be seasonality but given the proximity to Israel and the fact that strict entry requirements only lets fully vaccinated persons from Palestine to Israel we cannot be certain.


    Kid Immunization Commences

    Israel’s Prime Minister Naftali Bennett’s nine-year-old son was one of the first children to receive the shot. Bennett said the vaccination of children “safeguards both children and parents, and the entire State of Israel.”



    At the same time, according to HaAretz, Bennett has called for an antigen test in schools right after the Hanukkah break. The coronavirus cabinet also said that indoor restrictions should continue for another two weeks.


    The “R” Number

    Prof. Eran Segal of the Weitzman Institute, who is advising the cabinet said that the level of immunity of the vaccines has fallen since November, and this “reflected by the rise in the number of confirmed cases.” According to Segal, the reasons for the increase in the R number, which is the number each infected coronavirus carrier infects, is because restrictions have been relaxed, the rise of infections in children, and a lapse of immunity in the public.


    As Segal says: “In this reality, vaccines aren’t enough to stop the [coronavirus] wave, and we need to continue using all the effective methods that minimize infection without hurting the economy.”


    The Israeli coronavirus advisory panel also recommended that public awareness should be “strengthened” as well as better enforcement of the “Green Pass,” which Israelis use to prove they’ve been vaccinated.


    The panel concluded by saying that there is no clear sign of a significant covid outbreak but there is a strong likelihood an outbreak “will occur.” The panel attributes this to waning immunity and delay in getting a booster shot.


    Call to Action: TrialSite will continue to monitor the Israeli press as well as communicate with community members in the country. The mass booster program commenced during the late summer and mainstream media declared a success by October as cases plummeted throughout September. With cases moving back up, TrialSite monitors this nation carefully


    PM’s son, 9, gets COVID vaccine as Israel officially launches shots for ages 5-11
    Coronavirus inoculation campaign kicks off with 2.5% of age group signed up; health officials warn of rising cases among kids
    www.timesofisrael.com

    While CDC Thumbs Up Mass Boosters America’s Leaders Must Come Together & Update Strategies to Fight COVID-19


    While CDC Thumbs Up Mass Boosters America’s Leaders Must Come Together & Update Strategies to Fight COVID-19
    The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendation to expand booster shots to all
    trialsitenews.com


    The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendation to expand booster shots to all people across the USA over 18 now has the endorsement of Director Rochelle P. Walensky, MD, MPH. The recommendation covers everyone 18 and up who received the Pfizer-BioNTech or Moderna vaccine at least six months after their second dose. This urgent move reflects the reality that the current crop of vaccine products on the market waned in effectiveness after half a year down to below 40% in effectiveness in the case of Pfizer-BioNTech’s BNT162b2, according to some real-world studies. Thus, with the Food and Drug Administration (FDA) authorization and CDC’s recommendation, the green light is on for mass booster jabs to commence immediately as the cold season arrives and cases could explode once again. But the current COVID-19-beating paradigm needs a rethink while yet another short-term measure for protection is taken.


    While nearly 50 million adults still haven’t been vaccinated, a fundamental chasm in understanding grows as one the one hand, much of the medical and health establishment buys into the paradigm that universal immunization is the only answer to stop the pandemic. At the same time, a growing list of experts starts to seriously question assumptions underlying such a position.


    TrialSite concurs with CDC that vaccination is a way to lower the risks of serious COVID-19—a condition that can lead to hospitalization and death—and we add a horrific death—one where loved ones often aren’t even allowed to see the severely ill family member. There are many reasons to get vaccinated during this pandemic.


    On the other hand, we receive a growing number of data points as to adverse events that are routinely not covered or taken seriously. This raises considerable concern that millions of Americans may ultimately struggle with issues that derive from the COVID-19 vaccines. TrialSite calls attention to this mounting problem—it will not be avoidable.


    Moreover, we must look critically at the approach as a continuous booster program year after year isn’t feasible either until we fully understand the impacts of the vaccine. The reality is that the current batch of early-stage vaccines on the market have durability challenges over time. This is normal as no such vaccine product can be perfect in the fact of such a highly mutating pathogen.


    Dr. Walensky went on the record last Friday declaring:


    “After critical scientific evaluation, today’s unanimous decision carefully considered the current state of the pandemic, the latest vaccine effectiveness data over time, and review of safety data from people who have already received a COVID-19 primary vaccine series and booster. Booster shots have demonstrated the ability to safely increase people’s protection against infection and severe outcomes and are an important public health tool to strengthen our defenses against the virus as we enter the winter holidays. Based on the compelling evidence, all adults over 18 should now have equitable access to a COVID-19 booster dose.”


    Waning Impact

    While Bill Gates recently admitted that vaccines work well as a health tool, new U.S. data further support the concern that the jab don’t stop infections at nearly the rates that they do upon first shot.


    For example, unvaccinated persons were about five times more likely to test affirmative for SARS-CoV-2 than those vaccinated by Sept. 26. However, this represents a substantial performance decline from 15 times more probably in May reports the CDC with their latest age-adjusted data.


    Call to Action: TrialSite suggests that health systems must be prepared for a reality that increasing vaccination won’t stop infection and that moves to lock down and force vaccination on hold-outs will trigger perverse social and political reactions, including the potential for unrest. Instead, cooler heads prevail all the way now: what might be considered political adversaries should now come together and formulate updated approaches to coexisting with SARS-CoV-2 as the inevitable endemic stage approaches. A combination of antiviral early-stage treatment, home healthcare, vaccination, data-driven, risk-based public health strategies, and an open mind is critically important at this juncture


    CDC Newsroom
    Press releases, advisories, telebriefings, transcripts and archives.
    www.cdc.gov

    Attorney, Sentara quiet over Dr. Marik's hospital suspension


    Attorney, Sentara quiet over Dr. Marik's hospital suspension


    NORFOLK, Va. - It remains unclear why Dr. Paul Marik has been suspended from his hospital privileges at Sentara Norfolk General Hospital.


    Marik's attorney told News 3 Monday Marik found out Saturday when he reported to work that his hospital privileges had been suspended for 14 days at the hospital.


    The attorney, Fred Taylor, told News 3 Tuesday he couldn't comment further because the information is considered privileged.


    Sentara also declined to comment further, writing in a statement, "At Sentara Healthcare, we care for all patients and consider every individual a person of sacred worth and value. In accordance with applicable state statutes, and consistent with hospital policies, we cannot comment on any medical staff proceedings. We will continue to remain focused on providing excellent patient care."


    Marik, a critical care doctor at Sentara Norfolk and professor of medicine and chief of pulmonary and critical care medicine at Eastern Virginia Medical School in Norfolk, is in the midst of a legal battle over use of ivermectin.


    Marik sued Sentara because he believes the drug can help kill the COVID-19 virus. Last week, the case played out in court with a ruling expected in the case soon.


    Major health groups, including the U.S. Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health, say there’s not enough data to prove ivermectin works against the virus.


    Marik is suing the healthcare system because they won't allow him to treat COVID-19 patients with ivermectin, along with a host of other drugs that make up his developed MATH+ Protocol.


    In a letter, Marik's attorney said the suspension letter was dated Nov. 18, the same date as the hearing last week.


    “This is a desperate attempt by Sentara to say that Dr. Marik does not have standing since he was suspended at the time of arguing his case in court,” Taylor told News 3.


    Late Tuesday, the judge denied Marik's attempt to be able to prescribe ivermectin to COVID-19 patients.


    The Norfolk Circuit Court Clerks Office said the court denied in part Sentara Healthcare's lack of standing motion and denied Marik's temporary injunction motion.

    While we are disappointed that the Court did not grant the temporary injunction, our case for the rights of doctors and their patients remains alive and well. We expect to ultimately succeed on the merits of our case at trial," Taylor said in a statement to News 3 after the ruling.


    Marik says he's never actually prescribed ivermectin for COVID-19 patients, but his attorney says he's relied on research and studies to come to the belief that it's safe and effective in treating them.


    A paper he co-authored for a medical journal about his treatment plan was retracted due to the concerns about the data.


    Several studies remain ongoing into whether or not ivermectin is an effective treatment for COVID-19. A recent interim review of a trial going on through the National Institutes of Health found no overly beneficial impact, but the trial is still continuing.

    Limited immune responses after three months of BNT162b2 vaccine in SARS-CoV-2 uninfected elders living in long-term care facilities


    Limited immune responses after three months of BNT162b2 vaccine in SARS-CoV-2 uninfected elders living in long-term care facilities
    Background SARS-CoV-2 vaccination is the most effective strategy to protect elders living in long-term care facilities (LTCF) against severe COVID-19, but…
    www.medrxiv.org


    Abstract

    Background SARS-CoV-2 vaccination is the most effective strategy to protect elders living in long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses are less effective in older adults. Here, we characterized the humoral responses following 3 months after mRNA/BNT162b2 vaccine in institutionalized elders.


    Methods Plasma levels of specific SARS-CoV-2 total IgG, IgM and IgA antibodies were measured before and 3 months after vaccination in elders living in LTCF. Neutralization capacity was assessed in a pseudovirus neutralization assay against WH1 (original) and B.1.617.2/Delta variants. A group of younger adults was used as reference group.


    Results Three months after vaccination, uninfected-elders presented reduced specific SARS-CoV-2 IgG levels and significantly lower neutralization capacity against the WH1 and Delta virus compared to vaccinated uninfected younger individuals. In contrast, COVID-19 recovered elders showed significantly higher specific SARS-CoV-2 IgG levels after vaccination than younger counterparts, while showing similar neutralization activity against WH1 virus and increased neutralization capacity against Delta variant. Despite previously infected elders elicit potent cross-reactive immune responses similarly to younger individuals, higher quantities of specific SARS-CoV-2 IgG antibodies are required to reach the same neutralization levels.


    Conclusions While hybrid immunity seems to be active in previously infected elders after three months from mRNA/BNT162b2 vaccination, humoral immune responses are diminished in COVID-19 uninfected vaccinated residents living in LTCF. These results suggests that a vaccine booster dose should be prioritized for this particularly vulnerable population.

    Quote from Wyttenbach

    ...

    Worst effect of CoV-19 all media coordinated by the FM/R/J/B mafia. Usually the same fake news everywhere like "almost all ICU cases non vaxx" OR "vaccines" will help despite the unvaxx young very rarely die....

    ...

    Even fake news in Switzerland, it seems...current ICU rates in Zürich: a factor of more than 3 between unvaxx (blue) and double vaxx (red). Probably similar across the country. Declining, but still more than significant. Or do I read this chart completely wrong?


    https://www.zh.ch/content/dam/zhweb/bilder-dokumente/themen/gesundheit/corona/hauptseite/gd_zh_corona_lagebulletin.pdf


    Quote from zorud

    Wyttenbach knows of course. Maybe he can find out the sources of the numbers of those who need intensive care and ventilation (probably a fraction of those in the table who show up at emergency care and require more care and overnight stay...)?

    This is easy to deduce. Just look at the deaths. This is also 9:1 (age 80+) 6:1 (age 70..79) "double vaxx" : unvaxx. Most people die in hospitals today.

    Quote from Fm1

    "At Sentara Healthcare, we care for all patients and consider every individual a person of sacred worth and value.

    This is a fascist Euphemism. Looks like going to an US hospital with CoV-19 today is a death sentence...Worst:: The legal system upholds fascist decisions that are against all actual legal rules for medicine.

    If such judges shine up, as a doctor, I would no longer treat them.

    Quote from zorud

    Even fake news in Switzerland, it seems...current ICU rates in Zürich: a factor of more than 3 between unvaxx (blue) and double vaxx (red). Probably similar across the country.

    I know that children only know black and white. The fake news is almost all are unvaxx. Here in Switzerland we also count recovered into the vaccinated group. So you have to half the vaccine group to get the real ICU picture. unvaxx: vaxx 2:1. Currently the unvaxx group did grow due to a larger part of younger people affected. But age < 50 has > 1000x less risk than age 80+.


    The last complete Switzerland data set is from 15.11.2021 https://www.covid19.admin.ch/de/vaccination/status (Fälle nach Impfstatus.)


    It looks like vaxx: unvaxx rate is close to 1:1 now, what is very disappointing. (Status unknown is usually vaxx but no document ready) But the vaxx group is now 2/3 of the population - so vaccine protection from hospital still is 50%.


    You can always find a place with a different rate. E.g. Zürich is a central hospital that also takes patients from other places.

    Also data needs some time 1-2 weeks to show up!


    The only fact is vaccine play a minor role. Treatment would be needed!

    Quote from zorud

    That would mean, almost all ICU patients in all age groups die?

    Children logic again. The rate is the same! Going to hospital ICU rate = dying rate. But for age group 80+ it really looks the same. Almost all going to ICU die...But this ICU death rate goes down to 10%, 5%,3% for younger age groups. Further the younger shine up in much smaller figures!

    Detailed data in ::https://assets.publishing.serv…llance-report-week-46.pdf


    Age group 80+ really looks bad!


    11863 PCR+ --> 1821 ICU --> 1751 deaths. So in UK for 80+ it really looks not good. Same here too.80+ has 120x higher death rate than age 50..59. https://www.covid19.admin.ch/de/epidemiologic/death

    Quote from Nar

    The UK stats given are clearly not ICU stats though. I don't know what the ICU stats are.


    Between 14 July and 2 September 2021, 203 patients with Covid-19 were admitted to intensive care units (ICU) across north east London (NEL). Of these, 90% (181) were not fully vaccinated, with most tending to be on average six years younger than patients admitted to ICU who are fully vaccinated.


    Almost 90% of patients admitted to Intensive Care Units in north east London are not fully vaccinated - NHS North East London CCG
    Between July and September 2021, 203 patients with Covid-19 were admitted to intensive care units (ICU) across north east London (NEL). Of these, 90% (181)…
    northeastlondonccg.nhs.uk



    Figures released by the Department of Health (DoH) showed that on Thursday this week, of those in Intensive Care Units (ICUs ) with Covid, 72% were unvaccinated, 8% had one dose and 20% had been double jabbed.


    Almost 75% of Covid patients in ICU wards have had no jab
    The latest figures show how effective the Covid jabs have been - with a massive 72% of those in critical care wards not having been vaccinated.
    www.newsletter.co.uk

    Quote from Wyttenbach

    Here in Switzerland we also count recovered into the vaccinated group.

    Is there a source (who is "we")? Would be interesting, also for the German and Austrian numbers to better differentiate. I haven't seen any statistics that clearly outlines, that the double vaxx group includes all from a Covid-19 infection recovered patients, that are unvaxx. "Double vaxx" by definition here in Germany ncludes recovered + at least one vaccination.

    Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin


    https://www.tandfonline.com/doi/full/10.1080/21505594.2021.2006960


    Abstract

    The struggle to control the COVID-19 pandemic is made challenging by the emergence of virulent SARS-CoV-2 variants. To gain insight into their replication dynamics, emergent Alpha (A), Beta (B) and Delta (D) SARS-CoV-2 variants were assessed for their infection performance in single variant- and co-infections. The effectiveness of thapsigargin (TG), a recently discovered broad-spectrum antiviral, against these variants was also examined. Of the 3 viruses, the D variant exhibited the highest replication rate and was most able to spread to in-contact cells; its replication rate at 24 h post-infection (hpi) based on progeny viral RNA production was over 4 times that of variant A and 9 times more than the B variant. In co-infections, the D variant boosted the replication of its co-infected partners at the expense of its own initial performance. Furthermore, co-infection with AD or AB combination conferred replication synergy where total progeny (RNA) output was greater than the sum of corresponding single-variant infections. All variants were highly sensitive to TG inhibition. A single pre-infection priming dose of TG effectively blocked all single-variant infections and every combination (AB, AD, BD variants) of co-infection at greater than 95% (relative to controls) at 72 hpi. Likewise, TG was effective in inhibiting each variant in active pre-existing infection. In conclusion, against the current backdrop of the dominant D variant that could be further complicated by co-infection synergy with new variants, the growing list of viruses susceptible to TG, a promising host-centric antiviral, now includes a spectrum of contemporary SARS-CoV-2 viruses.


    Discussion

    A key finding from single-variant comparisons of SARS-CoV-2 infection is that the D variant is superior to the A and B variants in replication rate and in cell-to-cell transmission. Technically, the use of FFA in virus quantification, but not the use of median tissue culture infectious dose (TCID50) assay (Al-Beltagi et al., 2021; Coleman and Frieman, 2015), has an added advantage of visualising and quantifying infected cell clusters from direct collateral spread of SARS-CoV-2. Our in vitro finding of high replication rate of the D variant is consistent with a recent finding that in nasopharyngeal samples, virus load of the Delta variant was 2.5-fold higher (p < 0.05) than that of the Beta variant (Teyssou et al., 2021); and with a pre-print report based on clinical cases that found the D variant to proliferate more rapidly and accumulate to much higher levels (~100 times higher) in the respiratory tract than the first wave of 2020 variants (Li et al., 2021).


    This work has also highlighted that co-infection in certain SARS-CoV-2 variant combinations, such as the AD or AB pairing, can result in replication synergy. AD co-infection was particularly striking in that the A variant was quantitatively dominant over and at the expense of the D variant in progeny RNA production. Although there was no significant change in total infectious progeny, as detected by 18 h FFAs, between A variant single-infection and AD co-infection, we should closely monitor events of co-infection, in particular of new variants, for disease severity and population spread as the dynamics of virus replication in co-infection are unpredictable and can differ sharply from corresponding single-virus infections. In a case study, co-infection by two SARS-CoV-2 lineages, 20A and 20B, was thought to contribute to the extended duration and severity of disease in a 17-year-old patient (Pedro et al., 2021).


    The worrying breakthrough rate of D variant infection amongst fully vaccinated individuals suggests that current vaccines are less able to block virus proliferation to prevent transmission. The rapid replication rate and cell-to-cell spread of the D variant are likely viral traits responsible for infection breakthrough in fully vaccinated individuals. The ability of the D variant to rapidly spread through cells by direct contact without the prior need of extracellular progeny release could partly shield the virus from an existing humoral response. To tackle disease fallout from increased virus pathogenicity, infectivity and replication synergy, future management of COVID-19 may well require the use of contemporary multivalent vaccines, combined with effective broad-spectrum antivirals that can preferably be administered orally. We previously showed that the antiviral use of TG was highly effective against influenza viruses of different subtypes (Goulding et al., 2020), respiratory syncytial virus, coronavirus OC43 and an original isolate of SARS-CoV-2 (2019-nCoV/Italy-INMI1, clade V) (Al-Beltagi et al., 2021). Other groups have reported effective TG inhibition of paramyxoviruses (Kumar et al., 2019), and 229E, Middle-East respiratory syndrome and SARS-CoV-2 coronaviruses (Shaban et al., 2021). All available data (generated by us and others) as exemplified in influenza virus, RSV and coronaviruses, including SARS-CoV-2, indicate that TG does not prevent viral entry but rather triggers intracellular pathways to inhibit virus replication (Al-Beltagi et al., 2021; Goulding et al., 2020; Shaban et al., 2021). As a host-centric antiviral, TG hits several central host mechanisms connected to endoplasmic reticulum stress-unfolded protein response to inhibit several stages of virus replication. The antiviral potency of TG has now been extended to contemporary SARS-CoV-2 variants, including the D variant, in all combinations of single- and co-infections. We therefore submit that TG is potentially a truly broad-spectrum antiviral that targets a growing list of viruses.


    Thapsigargin—From Traditional Medicine to Anticancer Drug
    A sesquiterpene lactone, thapsigargin, is a phytochemical found in the roots and fruits of Mediterranean plants from Thapsia L. species that have been used for…
    www.ncbi.nlm.nih.gov


    sesquiterpene lactone, thapsigargin, is a phytochemical found in the roots and fruits of Mediterranean plants from Thapsia L. species that have been used for centuries in folk medicine to treat rheumatic pain, lung diseases, and female infertility

    Quote from Wyttenbach

    Children logic again. The rate is the same! Going to hospital ICU rate = dying rate.

    Glad to not live in Switzerland where all IPS patients seem to die anyway... :(


    How to read this report then??? Says survival rate is 75%? Not sure if the report says something about the ratio double vaxx vs unvaxx...

    (Sorry for no link, it is behind a paywall...but you can google, from early September 2021

    )

    Quote from Zeus46

    Between 14 July and 2 September 2021,

    You make the same Mistake as our clown. Read the headline once more. From 14th July.....


    Only actual data counts no historic dilution/ faking allowed...

    Quote from zorud

    I haven't seen any statistics that clearly outlines, that the double vaxx group includes all from a Covid-19 infection recovered patients, that are unvaxx.

    The establishment still tries to hide this cheating. Here all recovered got 2 jabs until late 2020. Then they did read the first papers and reduced it to 1 jab. Now no jab is needed if you have anti bodies. Not so in big pharma countries USA end EU.


    I also know from personal contacts that nurses have been forced to hide the number of double vaxx patients. But this game now is over as the state now requests the data. May be some places still try to hide the facts. E.g. a lot of "unknowns" are reported but usually "unknown vaccination status" is vaxx as people exactly know they are unvaxx....

Subscribe to our newsletter

It's sent once a month, you can unsubscribe at anytime!

View archive of previous newsletters

* indicates required

Your email address will be used to send you email newsletters only. See our Privacy Policy for more information.

Our Partners

Supporting researchers for over 20 years
Want to Advertise or Sponsor LENR Forum?
CLICK HERE to contact us.